EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: transformation to SCLC from EGFR-mutated squamous cell lung carcinoma during osimertinib treatment

Takashi Yamana, Kazuhiko Hirano, Risa Yoshioka, Yusuke Mizuhashi, Kasumi Tsukamoto, Yukiko Abe, Hiroaki Kodama, Mitsuhiro Kamimura

Frontiers in Oncology · 29.07.2026 · 16

DOI: 10.3389/fonc.2026.1822365 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 29.07.2026. Verfasst von Takashi Yamana und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, National Hospital Organization Disaster Medical Center, Tokyo, Japan. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Somatic EGFR mutations are prevalent in lung adenocarcinoma but are exceptionally rare in primary squamous cell carcinoma (SCC). Consequently, while histologic transformation to small cell lung carcinoma (SCLC) is an established resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) in adenocarcinoma, its occurrence in EGFR-mutated SCC remains virtually uncharacterized, representing a significant knowledge gap in thoracic oncology. Case description We report the case of a 42-year-old male initially diagnosed with stage IIIA EGFR-mutated SCC. Following definitive chemoradiotherapy, the patient experienced disease recurrence and was sequentially treated with erlotinib plus ramucirumab, followed by osimertinib. Upon clinical progression during osimertinib therapy, a repeat biopsy was performed. Pathological and immunohistochemical evaluations revealed a complete phenotypic shift from the initial TTF-1-negative, p40-positive SCC to a TTF-1-positive SCLC, while retaining the original EGFR exon 19 deletion. The patient exhibited a favorable clinical response to a subsequent regimen of carboplatin, etoposide, and durvalumab.

Conclusion

The retention of the EGFR mutation in the present case enabled the definitive diagnosis of histologic transformation from the original squamous cell carcinoma, confirming a shared clonal origin rather than a second primary malignancy. This case underscores the critical clinical necessity of routine resistance monitoring and repeat biopsies with comprehensive histological profiling at the time of TKI failure, regardless of the initial non-small cell lung cancer histology”.

Schlagwörter

Stichwörter der Autor:innen

EGFRSCC (squamous cell cancer)SCLCosimertinibtransformation

Autor:innen und Institutionen

  • Department of Pulmonology, National Hospital Organization Disaster Medical Center, Tokyo, Japan.
  • Laboratory and Pathology Division, National Hospital Organization Disaster Medical Center, Tokyo, Japan.

Zitieren

APA

Yamana, T., Hirano, K., Yoshioka, R., Mizuhashi, Y., Tsukamoto, K., Abe, Y., Kodama, H., & Kamimura, M. (2026). Case Report: transformation to SCLC from EGFR-mutated squamous cell lung carcinoma during osimertinib treatment. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1822365

Vancouver

Yamana T, Hirano K, Yoshioka R, Mizuhashi Y, Tsukamoto K, Abe Y, et al. Case Report: transformation to SCLC from EGFR-mutated squamous cell lung carcinoma during osimertinib treatment. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1822365

BibTeX
@article{Yamana2026,
  author = {Yamana, Takashi and Hirano, Kazuhiko and Yoshioka, Risa and Mizuhashi, Yusuke and Tsukamoto, Kasumi and Abe, Yukiko and Kodama, Hiroaki and Kamimura, Mitsuhiro},
  title = {Case Report: transformation to SCLC from EGFR-mutated squamous cell lung carcinoma during osimertinib treatment},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1822365}
}
Kostenlos starten →